219 related articles for article (PubMed ID: 20089875)
1. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Yang H; Jager MJ; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2835-42. PubMed ID: 20089875
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma.
Sharma RK; Balaiya S; Chalam KV
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6906; author reply 6906-7. PubMed ID: 21123801
[No Abstract] [Full Text] [Related]
3. Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model.
Yang H; Akor C; Dithmar S; Grossniklaus HE
Mol Vis; 2004 Dec; 10():987-95. PubMed ID: 15623988
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab and intraocular tumors: an intriguing paradox.
el Filali M; Ly LV; Luyten GP; Versluis M; Grossniklaus HE; van der Velden PA; Jager MJ
Mol Vis; 2012; 18():2454-67. PubMed ID: 23077404
[TBL] [Abstract][Full Text] [Related]
5. In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases.
Yang H; Fang G; Huang X; Yu J; Hsieh CL; Grossniklaus HE
Melanoma Res; 2008 Apr; 18(2):95-103. PubMed ID: 18337645
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells.
Yang H; Dithmar S; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2056-64. PubMed ID: 15223777
[TBL] [Abstract][Full Text] [Related]
7. Role of IL-8 induced angiogenesis in uveal melanoma.
Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
9. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
[TBL] [Abstract][Full Text] [Related]
10. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model.
Yang H; Grossniklaus HE
Curr Eye Res; 2006 Jun; 31(6):557-62. PubMed ID: 16769615
[TBL] [Abstract][Full Text] [Related]
11. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model.
Yang H; Xu Z; Iuvone PM; Grossniklaus HE
Mol Vis; 2006 May; 12():511-7. PubMed ID: 16735992
[TBL] [Abstract][Full Text] [Related]
12. Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma.
Crosby MB; Yang H; Gao W; Zhang L; Grossniklaus HE
Br J Ophthalmol; 2011 Jan; 95(1):112-7. PubMed ID: 20819828
[TBL] [Abstract][Full Text] [Related]
13. Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis.
Yang H; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):28-34. PubMed ID: 19661223
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
Han YS; Lee JE; Jung JW; Lee JS
Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
[TBL] [Abstract][Full Text] [Related]
15. Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines.
Dithmer M; Kirsch AM; Richert E; Fuchs S; Wang F; Schmidt H; Coupland SE; Roider J; Klettner A
Mar Drugs; 2017 Jun; 15(7):. PubMed ID: 28640204
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab treatment of meningeal melanoma metastases.
Simonsen TG; Gaustad JV; Rofstad EK
J Transl Med; 2020 Jan; 18(1):13. PubMed ID: 31915016
[TBL] [Abstract][Full Text] [Related]
19. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma.
Hu K; Babapoor-Farrokhran S; Rodrigues M; Deshpande M; Puchner B; Kashiwabuchi F; Hassan SJ; Asnaghi L; Handa JT; Merbs S; Eberhart CG; Semenza GL; Montaner S; Sodhi A
Oncotarget; 2016 Feb; 7(7):7816-28. PubMed ID: 26761211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
